PHARMACEUTICAL INDUSTRY RESEARCH ASSOCIATION

Founded in 1990, we are a non-profit sector entity, representing the national and international companies and researchers responsible for health innovation in Brazil.

Our members seek, through innovation, to promote and encourage the development of the industry of scientific and technological research in the country, medication and products to improve the health of the population.

The minimum requirements to be part of our entity are: 1. Carry out radical research and 2. Follow our Code of Practice.

Researchers, institutions, foundations, universities, institutes, start-ups and even individuals can be members. For more information, check Interfarma’s  Social Statute.

A Interfarma | About us
Interfarma in the Brazilian Market

Interfarma in the Brazilian Market

Brazil stands out in the world pharmaceutical panorama, currently moving between 6th and 7th
position. At this rate of growth, it is estimated that the country will attain 5th position in 2023.

Our members have accounted for at least half of the domestic pharmaceutical market for over ten years. From 2005 to 2018, the average percentage of participation was 53% (Interfarma Guide 2020), according to turnover published in commercial reports for the pharmaceutical industry.

Representation of associates in Brazilian retail

Interfarma in the Brazilian Market

Interfarma and its members are committed to improving patient access to new technologies, drugs and innovative treatments. In the approximately nine years of existence of CONITEC (National Commission of Incorporation of Technologies in the SUS), our members have had a total of 216 drugs approved for incorporation. Of the 153 applications made by associated members, 59 were accepted, meaning a success rate of 40.5%. When the applicant was the SUS, this rate rose to 76.

Patient Support Programs (PSPs) are another way of expanding and improving access to drugs and treatments in Brazil. According to data from the 2020 Sustainability Report, in 2019, 68% of companies (21 of the 31 that responded) have programs of this type and 90% of them adopt practices that allow patient satisfaction evaluation regarding service within the program. Twelve associates invested R$ 4.6 million and more than 10 million people benefitted from these programs.

In addition to this, research and innovation are in the DNA of the pharmaceutical industry. In 2019, the amount invested by 19 associates was US$ 80.1 billion worldwide. In Brazil, 12 associates invested R$ 657 million. There were 483 molecule development programs and projects (pre-clinical research and clinical research) by 15 associates and 183 clinical studies, with investments of more than R$ 573.4 million, in Brazil.

Through our associates, we also contribute to campaigns on the correct use of drugs, the importance of vaccination, among others. In 2019, 77% of companies had structured educational programs, geared towards health professionals, for example. In all, 105,951 health professionals were reached with initiatives carried out in the year.

Data from 2019 reflect the years of efforts made by companies for more diversity, mainly concerning gender. From 2017 to 2019, there was a significant growth, with 49% of employees being men and 51% women, whereas in 2017, 57% were men and 43% women. Also according to the 2020 Sustainability Report, taking into account the companies who replied, 37% of the Administrative Council were women, and 3% were black. In leadership positions, considering coordination level and above, there was an increase in female participation. In 2019, women accounted for 52% of leadership positions, as against 23% in 2017.

Interfarma | Entity Commitment

PURPOSE AND ACTION

One of our main activities is to establish a constant channel of communication between society, the pharmaceutical sector and federal, state and municipal governments. We actively participate in public consultations and are always keep close ties to everyone involved in a process, to help find the best solution.

Our decisions and way of dialoguing with the government and society in the most transparent way possible, are always in a frank, open, professional, respectful manner and, above all,  according to the most rigorous ethical standards. Ethics are not merely associated with our name, but are a hallmark of all our actions.

Purpose: To be the main source of interlocution and publicity in the pharmaceutical industry as a provider of value in health.   

To create conditions favorable to innovation, always ethically and transparently in processes and relations.

Action: To propose joint solutions for the sustainability of health systems, facilitating access of the population to quality of life, with prevention, treatment and cure.

To contribute to the generation of innovation for society and the development of the country.

CORPORATIVE GOVERNANCE

CHARTER OF PRINCIPLES

On its 25th anniversary, in 2015, Interfarma published the Charter of Principles and publicly assumed the commitment to look out for health and quality of life of Brazilian patients.
We are also committed to following the most rigorous standards of ethics and transparency, based on foundations considered permanent and irrevocable.

Ethic

CODE
OF PRACTICE
AND ETHICS

Our Code of Practice guides the relation between pharmaceutical companies associated to INTERFARMA, other adherent organizations and professionals in the health area, with an effective self-regulating channel.   

In 2007, we became the first entity in the pharmaceutical sector to have a code of practice to guide this relation. Its content is totally founded on such values as ethics, trust, transparency and integrity, with a view to the well-being of society and with the patient at the center of this care.      

The code is revised periodically and, since 2012, has helped the understanding of good practices with the medical class, established in partnership with the CFM (Federal Medical Council), the AMB (Brazilian Medical Association) and the SBC (Brazilian Society of Cardiology). This approval was fundamental for the transformation of our Code of Practice into a reference for Healthcare Compliance in Brazil. It is recognized not only by the pharmaceutical sector, but also by other segments of the Health Sector.     

Up to the launching of Code of Practice in current use (revised 2016), we were the first Pharmaceutical Industry Association to have an independent Ethics Committee, made up of internal and external members, an Internal Affairs department and a Conciliation sphere. This gives us total Independence regarding decisions made by us.   

In 2019, a new revision of this document was begun, which will be launched in the first semester of 2021.

ORGANIZATIONAL STRUCTURE

ORGANIZATIONAL STRUCTURE

INTERFARMA´s board of directors consists of 16 General Managers of associated companies, of whom 6 are part of the Management Committee, a group responsible for assisting in decision making and adjusting activities in the Entity´s governance system.   

We also have a Fiscal Board made up of professionals nominated by associates, with an executive team responsible for the execution of the strategic plan defined throughout the year by the Board of Directors.

Interfarma | WORKING GROUPS

PERMANENT COMMISSIONS, THEMATIC CHAMBERS AND WORK GROUPS

The most important issues in the pharmaceutical sector are under constant debate in nine commissions and four thematic chambers. Meetings serve to orient and update our associates, discuss our actions and search for unity in the sector, improving conditions for an innovative market, guided by ethics.  

The commissions are transversal and discuss themes of interest to the majority of our associates. The thematic chambers concentrate on more specific subjects, such as some products and market segments, and because of this, they have only the participation of interested pharmaceutical companies. Besides this, there are work groups, created to meet particular demands, which could interest all associates or just some of them.

PERMANENT COMMISSIONS

Access Commission

Access Commission

Social Responsibility Committee

Social Responsibility Committee

Compliance Committee

Compliance Committee

Communication Committee

Communication Committee

Legal Committee and IP

Legal Committee and IP

Economic Affairs Committee

Economic Affairs Committee

Regulatory Committee

Regulatory Committee

Clinical Research Committee

Clinical Research Committee

Institutional Relations Commission (Advocacy)

Institutional Relations Commission (Advocacy)

THEMATIC CHAMBERS

Biological Chamber

Biological Chamber

Dermatological Chamber

Dermatological Chamber

Chamber of Rare Diseases

Chamber of Rare Diseases

Innovation Chamber

Innovation Chamber

Associates

Associates

Interfarma | Become an associate

Become an associate

    Ao nos fornecer suas informações, você concorda com a coleta, armazenamento e processamento de suas informações, conforme nossa política de privacidade que está disponível aqui.